Troy– Author –
-
Biopharma’s Bottleneck: Critical CDMO Capacity Shortage Hampers Advanced Therapy Development
Contract Pharma USA Overview A severe capacity crunch within Contract Development and Manufacturing Organizations (CDMOs) is impeding the biopharmaceutical industry. Recent data reveals nearly half of biopharma firms struggle to secure C... -
Nanomedicine Conquers Glioblastoma’s Blood-Brain Barrier: Revolutionizing Treatment via Targeted Delivery, Stimuli-Responsiveness, and AI
Drug Target Review UK Overview Nanomedicine is emerging as a critical solution to overcome the formidable blood-brain barrier (BBB) in treating glioblastoma (GBM), the most aggressive brain tumor. Researchers are developing advanced nano... -
Peking University Unveils SynTar LNPs: A Precision Breakthrough for Targeted mRNA Lung Delivery
SINOPEG China Overview Researchers at Peking University have developed an innovative SynTar lipid nanoparticle (SynTar LNP) platform, overcoming a critical bottleneck in targeted mRNA delivery to the lungs. This system significantly enha... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
乳がん治療向け次世代ADCの開発課題と進歩：送達生物学の最適化が成功の鍵
PubMed (Expert Opinion on Drug Delivery) USA Overview Expert Opinion on Drug Deliveryに掲載されたレビューは、乳がんの治療抵抗性疾患に対する次世代抗体薬物複合体（ADC）の開発における進歩と課題を統合的に評価しました。本レビューは、ADCの設計... -
FDA Designates Washington University’s WU-CART-007 as Breakthrough Therapy for T-Cell Malignancies: Allogeneic Anti-CD7 CAR T-Cell Therapy Achieves 73% Complete Remission
Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine USA Overview The FDA has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by Washington University Schoo... -
AI-Powered In Silico Design Revolutionizes RNA-LNP Therapies for Targeted Delivery and CRISPR Gene Editing
InSilicoMinds USA Overview In silico (computational) design is fundamentally transforming the development of lipid nanoparticle (LNP) and RNA therapeutics by enabling the precise optimization of LNP properties for tissue-specific drug de... -
ADCs Take Center Stage at HerHealth2026: A Promising Strategy for Refractory Breast and Gynecological Cancers
HerHealth2026 USA Overview At the recent HerHealth2026 conference, Antibody-Drug Conjugates (ADCs) emerged as a pivotal topic, underscoring their growing importance in treating breast and gynecological cancers. These innovative therapies... -
Entera Bio’s Oral Peptide Platform Advances to Phase 3 for Osteoporosis, Heralding a New Era for Injectable Therapeutics
Entera Bio, Inc. USA Overview Clinical-stage biopharmaceutical company Entera Bio has secured an agreement with the FDA to initiate a Phase 3 clinical trial for EB613, an oral parathyroid hormone (PTH) analog for postmenopausal osteoporo... -
BioRay Pharmaceutical Advances Novel Dual-Payload TROP2 ADC, BR113, into First-in-Human Clinical Trials
AllSci China Overview China's BioRay Pharmaceutical has initiated a first-in-human Phase I trial for BR113, an innovative dual-payload TROP2 antibody-drug conjugate (ADC) targeting patients with advanced solid tumors. BR113 distinguishes...
